United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan
Rhea-AI Filing Summary
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported an exercise-and-sale sequence involving company stock on July 17, 2026. Family trusts associated with the reporting person exercised 9,500 stock options at $135.42 per share and sold 9,500 common shares across 11 transactions at weighted-average prices ranging from $528.39 to $542.49.
All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026. After the reported trades, family trusts and related indirect holdings reported 324,443 common shares and 322,410 stock options remaining.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,500 shares ($3.82M approx. pre-tax spread)
Exercise and Sale
18 txns
Insider
ROTHBLATT MARTINE A
Role
Chairperson & CEO
Sold
9,500 shs ($5.10M)
Approx. gross sale proceeds
$5.10M
Approx. exercise cost
$1.29M
Approx. pre-tax spread
$3.82M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F1, F17 | 9,500 | $0.00 | -- |
| Exercise | Common Stock F1, F2 | 9,500 | $135.42 | $1.29M |
| Sale | Common Stock F1, F3, F2 | 240 | $528.91 | $127K |
| Sale | Common Stock F1, F4, F2 | 240 | $530.8333 | $127K |
| Sale | Common Stock F1, F5, F2 | 720 | $534.5681 | $385K |
| Sale | Common Stock F1, F6, F2 | 2,350 | $535.5258 | $1.26M |
| Sale | Common Stock F1, F7, F2 | 2,110 | $536.3588 | $1.13M |
| Sale | Common Stock F1, F8, F2 | 1,160 | $537.4466 | $623K |
| Sale | Common Stock F1, F9, F2 | 423 | $538.7026 | $228K |
| Sale | Common Stock F1, F10, F2 | 821 | $539.6266 | $443K |
| Sale | Common Stock F1, F11, F2 | 251 | $540.6925 | $136K |
| Sale | Common Stock F1, F12, F2 | 892 | $542.0634 | $484K |
| Sale | Common Stock F1, F13, F2 | 293 | $542.4309 | $159K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F14 | -- | -- | -- |
| holding | Common Stock F15 | -- | -- | -- |
| holding | Common Stock F16 | -- | -- | -- |
Holdings After Transaction:
Stock Option — 322,410 shares (Indirect, by Trust);
Common Stock — 628,049 shares (Indirect, by Trust);
Common Stock — 40,513 shares (Direct);
Common Stock — 166 shares (Indirect, by Spouse)
Footnotes (17)
- F1. This exercise of stock options and sale of the resulting shares of common stock was pursuant to a pre-arranged 10b5-1 trading plan adopted by the reporting person on November 7, 2025. This plan will continue until the earlier of: (a) the exercise of 1,734,410 stock options, all of which expire on March 15, 2027; or (b) December 31, 2026.
- F10. This transaction was executed in multiple trades at prices ranging from $539.14 to $540.12. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $540.20 to $541.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $541.37 to $542.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $542.38 to $542.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F15. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F16. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
- F17. Stock options held in a family trust as to which the Reporting Person shares investment power and the Reporting Person and immediate family members are beneficiaries.
- F2. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries.
- F3. This transaction was executed in multiple trades at prices ranging from $528.39 to $529.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $530.80 to $530.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $533.97 to $534.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $534.99 to $535.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $536.00 to $536.94. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $537.07 to $538.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $538.12 to $539.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 9,500 shares
Shares sold: 9,500 shares
Option exercise price: $135.42 per share
+4 more
7 metrics
Options exercised
9,500 shares
Common stock acquired via option exercise on July 17, 2026 at $135.42 per share
Shares sold
9,500 shares
Total common shares sold on July 17, 2026 across 11 transactions
Option exercise price
$135.42 per share
Exercise or conversion price for stock options exercised into common stock
Sale price range
$528.39–$542.49 per share
Combined low and high trade ranges from sale footnotes F3 through F13
Common shares held indirectly
324,443 shares
Indirect common stock position in family trusts after the reported sales
Options remaining in trust
322,410 options
Stock options held indirectly after exercising 9,500 options
Options under 10b5-1 plan
1,734,410 stock options
Maximum stock options subject to the Rule 10b5-1 trading plan, expiring March 15, 2027
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock options, family trusts, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"exercise of stock options and sale ... was pursuant to a pre-arranged 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock options financial
"exercise of 1,734,410 stock options, all of which expire on March 15, 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
family trusts financial
"Shares held in family trusts as to which the Reporting Person shares investment power"
exercise or conversion of derivative security financial
"Transaction code "M" describes Exercise or conversion of derivative security"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider stock transactions did UTHR’s CEO report on July 17, 2026?
United Therapeutics CEO Martine A. Rothblatt reported that family trusts exercised 9,500 stock options at $135.42 and sold 9,500 common shares on July 17, 2026, through 11 separate transactions at weighted-average prices between $528.39 and $542.49.
Were the UTHR insider transactions made under a Rule 10b5-1 plan?
Yes. The option exercise and share sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan remains in effect until the earlier of exercising 1,734,410 stock options expiring March 15, 2027, or December 31, 2026.
What is the size and duration of UTHR CEO’s Rule 10b5-1 option plan?
The Rule 10b5-1 plan covers up to 1,734,410 stock options, all expiring on March 15, 2027. It will continue until the earlier of exercising those options or December 31, 2026, providing a predefined framework for option exercises and related share sales.
What option terms applied to the UTHR CEO’s July 17, 2026 exercise?
On July 17, 2026, family trusts for UTHR’s CEO exercised 9,500 stock options with an exercise price of $135.42 per share. The underlying options, which expire on March 15, 2027, are part of the larger 1,734,410-option Rule 10b5-1 trading plan.